✦ LIBER ✦

Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

✍ Scribed by Smith, B.; Cohn, D.E.; Clements, A.; Tierney, B.J.; Straughn, J.M.

Book ID: 120393201
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 418 KB
Volume: 130
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2013.05.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is the progression free survival advanta

Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

✍ B. Smith; D. Cohn; A. Clements; B. Tierney; J. Straughn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Cost Effectiveness of Concurrent Gemcita

Cost Effectiveness of Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Compared With Standard Concurrent Cisplatin and Radiation in Patients with Stage IIB to IVA Carcinoma of the Cervix

✍ N. Phippen; C. Leath III; J. Chino; E. Jewell; L. Havrilesky; J. Barnett 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Cost effectiveness of concurrent gemcita

Cost effectiveness of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin compared with standard concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix

✍ N. Phippen; C. Leath; J. Chino; E. Jewell; L. Havrilesky; J. Barnett 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Cost effectiveness of concurrent gemcita

Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix

✍ Neil T. Phippen; Charles A. Leath III; Junzo P. Chino; Elizabeth L. Jewell; Laur 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Phase III, Open-Label, Randomized Study

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

✍ Duenas-Gonzalez, A.; Zarba, J. J.; Patel, F.; Alcedo, J. C.; Beslija, S.; Casano 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 167 KB

PCN89 A COST EFFECTIVENESS ANALYSIS DEMO

PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; A Castro Gómez; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB